Compare TLK & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLK | DVA |
|---|---|---|
| Founded | 1884 | 1994 |
| Country | Indonesia | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Misc Health and Biotechnology Services |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4B | 14.9B |
| IPO Year | 2002 | 2003 |
| Metric | TLK | DVA |
|---|---|---|
| Price | $11.11 | $190.61 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $222.29 |
| AVG Volume (30 Days) | ★ 2.7M | 803.5K |
| Earning Date | 11-17-2026 | 10-29-2026 |
| Dividend Yield | ★ 8.61% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 10.27 |
| Revenue | N/A | ★ $13,643,069,000.00 |
| Revenue This Year | $2.82 | $3.77 |
| Revenue Next Year | $1.73 | $4.15 |
| P/E Ratio | ★ $15.71 | $18.76 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $10.15 | $101.00 |
| 52 Week High | $23.52 | $247.49 |
| Indicator | TLK | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 40.29 | 55.12 |
| Support Level | $10.15 | $189.09 |
| Resistance Level | $15.28 | $197.83 |
| Average True Range (ATR) | 0.27 | 7.86 |
| MACD | 0.00 | 0.96 |
| Stochastic Oscillator | 38.81 | 75.00 |
PT Telkom Indonesia (Persero) Tbk is the integrated telecommunications provider in Indonesia. It also provides a wide range of other communication services, including telephone network, interconnection services, multimedia, data and internet communication-related services, satellite transponder leasing, leased line, intelligent network and related services, cable television, and VoIP services. It derives revenue from product lines: Mobile, Consumer, Enterprise, WIB, and Others. The firm has identified five reportable segments, namely B2C, B2B Infra, B2B ICT, International, and Others. The firm generates the majority of its revenue from the B2C segment.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.